Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Cardiovascular outcome studies Although multiple clinical trials evaluating cardiovascular events associated with GLP-1 RA use as the primary outcome are currently ongoing (Table 1), abundant non-primary outcome data are available from many clinical trials on the efficacy of GLP-1 RAs marketed earlier, such as exenatide (DURATION studies) and liraglutide (LEAD studies)
Side Effects & Safety Per REDEFINE 1 and the Lau (2021) phase 2 program, trial-reported adverse events include: Nausea -- most common (25-40%)
You are in a huge life transition
Other side effects are very rare
Both medications are highly effective for weight loss, but there are some key differences: Semaglutide (Ozempic/Wegovy): Primarily acts as a GLP-1 receptor agonist and has been shown to result in around 15-18% weight loss over time for many patients
